A Boston-based drugmaker recently added a newly approved non-opiate pain treatment to the list of drugs subject to its 340B [...] …
Category: Pharma Industry
Two influential U.S. senators—each with a distinct vision of 340B reform—told health center leaders yesterday that they remained committed to [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Four large drugmakers are urging a federal judge to strike down the government’s opposition to their controversial 340B rebate models [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A France-based drugmaker recently reinstated its contract pharmacy restrictions in Kansas following a successful challenge of the state’s contract pharmacy [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A federal judge late last week denied Sagebrush Health’s attempt to compel the government to reinstate many of its sites [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
South Dakota recently became the 12th state to introduce a 340B contract pharmacy access bill in 2025, and a Hawaii [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A major hospital advocacy group and two of its members are seeking to intervene in a high-profile federal court case [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
State provider groups are forcefully pushing back against a new dark money ad campaign they say is spreading “shameful” misinformation [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Georgia has become the 11th state to introduce a 340B contract pharmacy bill in the opening weeks of the 2025 [...] …